The natural history of lung function after lung transplantation for α(1)-antitrypsin deficiency.

Amit Banga, Thomas Gildea, Jeevanantham Rajeswaran, Haala Rokadia, Eugene H. Blackstone, James K. Stoller

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Lung transplantation (LT) is an established treatment for end-stage lung diseases, including chronic obstructive pulmonary disease (COPD) associated with α1-antitrypsin deficiency (AATD). We sought to compare the post-transplantation course of patients with AATD and AAT-replete COPD. Between June 1991 and January 2008, a total of 231 patients with AAT-replete COPD and 45 with AATD underwent LT at Cleveland Clinic. Data reviewed included baseline recipient, donor, and surgical data; all spirometry evaluations; acute cellular rejection (ACR) events; and survival data. Endpoints included temporal change in FEV1, severity of ACR, and survival. A longitudinal temporal decomposition model was used for analysis. Comparison of overall rates of FEV1 decline in AATD and AAT-replete patients with COPD showed no significant differences (P > 0.09). However, although the single LT patients had similar trends in FEV1 in both groups, patients with AATD with double LT declined faster (P < 0.002) than the AAT-replete patients. No differences in the frequency or severity of ACR episodes were observed (P = 0.32). Furthermore, there was no difference in early or late mortality between patients with AATD and patients with AAT-replete COPD (P > 0.09). Although overall the post-LT FEV1 slope, severity of ACR, and survival among patients with AATD is similar to that of AAT-replete patients with COPD, patients with AATD with double LT have a faster rate of FEV1 decline. These findings support the eligibility of patients with AATD for LT, and suggest the need for additional studies to better understand the difference between single and double LT in AATD.

Original languageEnglish (US)
Pages (from-to)274-281
Number of pages8
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume190
Issue number3
StatePublished - 2014

Fingerprint

Lung Transplantation
Natural History
Lung
Chronic Obstructive Pulmonary Disease
Survival
Spirometry
Lung Diseases
Transplantation
Tissue Donors

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

The natural history of lung function after lung transplantation for α(1)-antitrypsin deficiency. / Banga, Amit; Gildea, Thomas; Rajeswaran, Jeevanantham; Rokadia, Haala; Blackstone, Eugene H.; Stoller, James K.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 190, No. 3, 2014, p. 274-281.

Research output: Contribution to journalArticle

Banga, A, Gildea, T, Rajeswaran, J, Rokadia, H, Blackstone, EH & Stoller, JK 2014, 'The natural history of lung function after lung transplantation for α(1)-antitrypsin deficiency.', American Journal of Respiratory and Critical Care Medicine, vol. 190, no. 3, pp. 274-281.
Banga, Amit ; Gildea, Thomas ; Rajeswaran, Jeevanantham ; Rokadia, Haala ; Blackstone, Eugene H. ; Stoller, James K. / The natural history of lung function after lung transplantation for α(1)-antitrypsin deficiency. In: American Journal of Respiratory and Critical Care Medicine. 2014 ; Vol. 190, No. 3. pp. 274-281.
@article{8009ccaf9585481e8c3d44c7519eb73c,
title = "The natural history of lung function after lung transplantation for α(1)-antitrypsin deficiency.",
abstract = "Lung transplantation (LT) is an established treatment for end-stage lung diseases, including chronic obstructive pulmonary disease (COPD) associated with α1-antitrypsin deficiency (AATD). We sought to compare the post-transplantation course of patients with AATD and AAT-replete COPD. Between June 1991 and January 2008, a total of 231 patients with AAT-replete COPD and 45 with AATD underwent LT at Cleveland Clinic. Data reviewed included baseline recipient, donor, and surgical data; all spirometry evaluations; acute cellular rejection (ACR) events; and survival data. Endpoints included temporal change in FEV1, severity of ACR, and survival. A longitudinal temporal decomposition model was used for analysis. Comparison of overall rates of FEV1 decline in AATD and AAT-replete patients with COPD showed no significant differences (P > 0.09). However, although the single LT patients had similar trends in FEV1 in both groups, patients with AATD with double LT declined faster (P < 0.002) than the AAT-replete patients. No differences in the frequency or severity of ACR episodes were observed (P = 0.32). Furthermore, there was no difference in early or late mortality between patients with AATD and patients with AAT-replete COPD (P > 0.09). Although overall the post-LT FEV1 slope, severity of ACR, and survival among patients with AATD is similar to that of AAT-replete patients with COPD, patients with AATD with double LT have a faster rate of FEV1 decline. These findings support the eligibility of patients with AATD for LT, and suggest the need for additional studies to better understand the difference between single and double LT in AATD.",
author = "Amit Banga and Thomas Gildea and Jeevanantham Rajeswaran and Haala Rokadia and Blackstone, {Eugene H.} and Stoller, {James K.}",
year = "2014",
language = "English (US)",
volume = "190",
pages = "274--281",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "3",

}

TY - JOUR

T1 - The natural history of lung function after lung transplantation for α(1)-antitrypsin deficiency.

AU - Banga, Amit

AU - Gildea, Thomas

AU - Rajeswaran, Jeevanantham

AU - Rokadia, Haala

AU - Blackstone, Eugene H.

AU - Stoller, James K.

PY - 2014

Y1 - 2014

N2 - Lung transplantation (LT) is an established treatment for end-stage lung diseases, including chronic obstructive pulmonary disease (COPD) associated with α1-antitrypsin deficiency (AATD). We sought to compare the post-transplantation course of patients with AATD and AAT-replete COPD. Between June 1991 and January 2008, a total of 231 patients with AAT-replete COPD and 45 with AATD underwent LT at Cleveland Clinic. Data reviewed included baseline recipient, donor, and surgical data; all spirometry evaluations; acute cellular rejection (ACR) events; and survival data. Endpoints included temporal change in FEV1, severity of ACR, and survival. A longitudinal temporal decomposition model was used for analysis. Comparison of overall rates of FEV1 decline in AATD and AAT-replete patients with COPD showed no significant differences (P > 0.09). However, although the single LT patients had similar trends in FEV1 in both groups, patients with AATD with double LT declined faster (P < 0.002) than the AAT-replete patients. No differences in the frequency or severity of ACR episodes were observed (P = 0.32). Furthermore, there was no difference in early or late mortality between patients with AATD and patients with AAT-replete COPD (P > 0.09). Although overall the post-LT FEV1 slope, severity of ACR, and survival among patients with AATD is similar to that of AAT-replete patients with COPD, patients with AATD with double LT have a faster rate of FEV1 decline. These findings support the eligibility of patients with AATD for LT, and suggest the need for additional studies to better understand the difference between single and double LT in AATD.

AB - Lung transplantation (LT) is an established treatment for end-stage lung diseases, including chronic obstructive pulmonary disease (COPD) associated with α1-antitrypsin deficiency (AATD). We sought to compare the post-transplantation course of patients with AATD and AAT-replete COPD. Between June 1991 and January 2008, a total of 231 patients with AAT-replete COPD and 45 with AATD underwent LT at Cleveland Clinic. Data reviewed included baseline recipient, donor, and surgical data; all spirometry evaluations; acute cellular rejection (ACR) events; and survival data. Endpoints included temporal change in FEV1, severity of ACR, and survival. A longitudinal temporal decomposition model was used for analysis. Comparison of overall rates of FEV1 decline in AATD and AAT-replete patients with COPD showed no significant differences (P > 0.09). However, although the single LT patients had similar trends in FEV1 in both groups, patients with AATD with double LT declined faster (P < 0.002) than the AAT-replete patients. No differences in the frequency or severity of ACR episodes were observed (P = 0.32). Furthermore, there was no difference in early or late mortality between patients with AATD and patients with AAT-replete COPD (P > 0.09). Although overall the post-LT FEV1 slope, severity of ACR, and survival among patients with AATD is similar to that of AAT-replete patients with COPD, patients with AATD with double LT have a faster rate of FEV1 decline. These findings support the eligibility of patients with AATD for LT, and suggest the need for additional studies to better understand the difference between single and double LT in AATD.

UR - http://www.scopus.com/inward/record.url?scp=84907287137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907287137&partnerID=8YFLogxK

M3 - Article

C2 - 25003824

AN - SCOPUS:84907287137

VL - 190

SP - 274

EP - 281

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 3

ER -